Clinical Endoscopy

The Korean Society of Gastrointestinal Endoscopy (대한소화기내시경학회)
권호 표지
DOI QR코드

DOI QR Code

Efficacy and safety of intragastric balloon for obesity in Korea

  • Kwang Gyun Lee (Department of Internal Medicine, We Comfortable Clinic) ;
  • Seung-Joo Nam (Department of Internal Medicine, Kangwon National University School of Medicine) ;
  • Hyuk Soon Choi (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Korea University College of Medicine) ;
  • Hang Lak Lee (Division of Gastroenterology, Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine) ;
  • Jai Hoon Yoon (Division of Gastroenterology, Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine) ;
  • Chan Hyuk Park (Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine) ;
  • Kyoung Oh Kim (Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center) ;
  • Do Hoon Kim (Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jung-Wook Kim (Division of Gastroenterology and Hepatology, Department of Internal Medicine, Kyung Hee University School of Medicine) ;
  • Won Sohn (Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine) ;
  • Sung Hoon Jung (Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea)
  • Received : 2022.04.29
  • Accepted : 2022.08.18
  • Published : 2023.05.30
Download PDF
⟨ Previous Next ⟩

Abstract

Background/Aims: Intragastric balloon (IGB) is the only available endoscopic bariatric and metabolic therapy in Korea. End-ball (Endalis) has the longest history of clinical use among the IGBs available in Korea. However, little clinical data on this system have been reported. In this study, we aimed to evaluate the efficacy and safety of End-ball in Korea. Methods: We performed a retrospective cohort study of patients who underwent IGB insertion (End-ball) from 2013 to 2019. Demographic and anthropometric data were collected. The efficacy and safety of IGB treatment were analyzed. Results: In total, 80 patients were included. Mean age was 33.7 years and 83.8% were female. Initial body mass index was 34.48±4.69 kg/m2. Body mass index reduction was 3.72±2.63 kg/m2 at the time of IGB removal. Percent of total body weight loss (%TBWL) was 10.76%±6.76%. Percentage excess body weight loss was 43.67%±27.59%. Most adverse events were minor, and 71.4% of participants showed nausea, vomiting, or abdominal pain. Conclusions: IGB treatment showed good efficacy and safety profile in Korean patients with obesity. In terms of %TBWL and percentage excess body weight loss, the efficacy was similar to that in the Western population.

Keywords

Acknowledgement

This study was supported by the 2018 Olympus Korea grant from the Korean Gastrointestinal Endoscopy Research Foundation.

References

  1. Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet 2011;378:804-814.
  2. Storm AC, Abu Dayyeh BK, Topazian M. Endobariatrics: a primer. Clin Gastroenterol Hepatol 2018;16:1701-1704.
  3. Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology 2017;152:1791-1801.
  4. McCarty TR, Thompson CC. The current state of bariatric endoscopy. Dig Endosc 2021;33:321-334.
  5. Stimac D, Klobucar Majano vic S, Belancic A. Endoscopic treatment of obesity: from past to future. Dig Dis 2020;38:150-162.
  6. Choe Y, Kim JS, Kim BW. Short-term outcomes of intragastric balloon placement for obesity treatment. Korean J Helicobacter Up Gastrointest Res 2020;20:318-323.
  7. Pak HJ, Choi HN, Lee HC, et al. Effects of intragastric balloon on obesity in obese Korean women for 6 months post removal. Nutr Res Pract 2021;15:456-467.
  8. Kim BY, Kang SM, Kang JH, et al. 2020 Korean Society for the Study of Obesity guidelines for the management of obesity in Korea. J Obes Metab Syndr 2021;30:81-92.
  9. Tai CM, Lin HY, Yen YC, et al. Effectiveness of intragastric balloon treatment for obese patients: one-year follow-up after balloon removal. Obes Surg 2013;23:2068-2074.
  10. Ohta M, Kitano S, Kai S, et al. Initial Japanese experience with intragastric balloon placement. Obes Surg 2009;19:791-795.
  11. Ganesh R, Rao AD, Baladas HG, et al. The bioenteric intragastric balloon (BIB) as a treatment for obesity: poor results in Asian patients. Singapore Med J 2007;48:227-231.
  12. Mui WL, So WY, Yau PY, et al. Intragastric balloon in ethnic obese Chinese: initial experience. Obes Surg 2006;16:308-313.
  13. Cho JH, Bilal M, Kim MC, et al. The clinical and metabolic effects of intragastric balloon on morbid obesity and its related comorbidities. Clin Endosc 2021;54:9-16.
  14. Laing P, Pham T, Taylor LJ, et al. Filling the void: a review of intragastric balloons for obesity. Dig Dis Sci 2017;62:1399-1408.
  15. Keren D, Rainis T. Intragastric balloons for overweight populations: 1 year post removal. Obes Surg 2018;28:2368-2373.
  16. Marrero Torres RJ, Gregory F, Micames CG. Fluid-filled intragastric balloons are an effective and safe weight loss option across BMI and age ranges. Surg Endosc 2022;36:5160-5166.
  17. ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee, Abu Dayyeh BK, Kumar N, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc 2015;82:425-438.
  18. Ribeiro IB, Kotinda APST, Sanchez-Luna SA, et al. Adverse events and complications with intragastric balloons: a narrative review (with video). Obes Surg 2021;31:2743-2752.
  19. Neto MG, Silva LB, Grecco E, et al. Brazilian Intragastric Balloon Consensus Statement (BIBC): practical guidelines based on experience of over 40,000 cases. Surg Obes Relat Dis 2018;14:151-159.
  20. Tak YJ, Lee SY. Anti-obesity drugs: long-term efficacy and safety: an updated review. World J Mens Health 2021;39:208-221.
  21. Kim HO, Lee JA, Suh HW, et al. Postmarketing surveillance study of the efficacy and safety of phentermine in patients with obesity. Korean J Fam Med 2013;34:298-306.
  22. Lewis KH, Fischer H, Ard J, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity (Silver Spring) 2019;27:591-602.
  23. Mehta A, Shah S, Dawod E, et al. Impact of adjunctive pharmacotherapy with intragastric balloons for the treatment of obesity. Am Surg 2021;31348211038579.
  24. Sioulas AD, Polymeros D, Kourikou A, et al. Intragastric balloon left in the stomach for more than a year: two case reports. Obes Facts 2012;5:436-439.
  25. Genco A, Maselli R, Frangella F, et al. Intragastric balloon for obesity treatment: results of a multicentric evaluation for balloons left in place for more than 6 months. Surg Endosc 2015;29:2339-2343.